首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 生物科技 > 生物材料 > 美國的整形外科生醫材料市場:2012年
產業/市場分類
生物科技 (1574)
分子標靶治療學 (131)
生技設備 (354)
生物材料 (53)
生物標記 (155)
以基因為基之藥物開發 (202)
再生醫學 (119)
抗體和免疫 (189)
個人化醫學 (51)
基因治療學和RNAi (102)
市場調查報告書

美國的整形外科生醫材料市場:2012年

US Markets for Orthopedic Biomaterials 2012

出版商 Millennium Research Group
出版日期 2011年11月 商品編碼 225459
內容資訊 英文  
價格
US $ 6995 Web Access and PDF Download (Single user license)
US $ 10500 Web Access and PDF Download (Corporate use license)


美國的整形外科生醫材料市場:2012年 是由出版商Millennium Research Group在2011年11月所出版的。 這份英文市場調查報告書價格從美金6995起跳。

簡介

預計到2016年，美國的整形外科生醫材料市場在許多課題下穩定成長。

本報告提供美國的整形外科生醫材料市場相關分析，彙整臨床環境，產品概要，臨床實驗趨勢，品牌概要與競爭趨勢，市場資料分析，為您概述為以下內容。

摘要整理

第1章 臨床環境

  • 背景
    • 骨性關節炎
    • 膝關節軟骨損傷
  • 治療概要
    • 骨移植手術
    • 玻尿酸粘彈劑治療
    • 椎體間融合
    • 菌體濃度反饋系統治療
    • 膝關節軟骨修復
    • 治療方法的競爭
    • 新興治療方法及技術
  • 各國概要
    • 人口統計與經濟
    • 醫療制度
    • 法律制度
  • 第2章 產品
  • 概要
    • 涉及的產品
  • 骨移植
    • 功能
      • 自家移植片
      • 生長因子
      • 脫鹽骨基礎品質
      • 第1代合成骨移植
      • 第2代合成骨移植
      • 整形外科幹細胞產品
      • 非專用同類移植片
    • 差異化特性
    • 認證的適應
    • 新興產品
  • 玻尿酸粘彈劑產品
    • 功能
    • 差異化特性
    • 新興產品
  • 椎體間融合
    • 功能
  • 菌體濃度反饋系統
    • 功能
  • 膝關節軟骨修復
    • 功能
    • 新興產品

第3章 臨床實驗

  • 已完成的臨床實驗
  • 持續中臨床實驗

第4章 品牌及競爭分析

  • 概要
    • 競爭概要
    • 市場佔有率
    • 近幾年的活動
  • 骨移植市場
    • 競爭概要
    • 詳細的競爭趨勢
    • 目前市場佔有率
    • 近幾年的活動
  • 玻尿酸粘彈劑產品
    • 競爭概要
    • 詳細的競爭趨勢
    • 目前市場佔有率
    • 近幾年的活動
  • 椎體間融合
    • 競爭概要
    • 詳細的競爭趨勢
    • 目前市場佔有率
    • 近幾年的活動
  • 菌體濃度反饋系統
    • 競爭概要
    • 詳細的競爭趨勢
    • 目前市場佔有率
    • 近幾年的活動
  • 膝關節軟骨修復
    • 競爭概要
    • 詳細的競爭趨勢
    • 目前市場佔有率
    • 近幾年的活動

第5章 整形外科生醫材料市場預測

第6章 骨移植市場預測

第7章 玻尿酸粘彈劑市場預測

第8章 椎體間融合市場預測

第9章 菌體濃度反饋系統市場預測

第10章 膝關節軟骨修復市場預測

附錄A:調查方法

附錄B:用語

附錄C:參考資訊

圖表

目錄

Abstract

Through 2016, the market for orthopedic biomaterials in the US will exhibit solid growth despite various challenges. Most notably, the bone graft substitute (BGS) market, which accounts for over half of the revenues in this space, has seen its most prominent BGS revenue generator, INFUSE, face heightened scrutiny and negative media attention. The product thus saw significant revenue declines in 2011. In addition to BGS, the US orthopedic biomaterial market includes hyaluronic acid (HA) viscosupplementation, knee cartilage repair, machined bone interbody devices (IBDs), and cell concentration systems. HA viscosupplementation will exhibit the most substantial growth within this market due to gravitation toward premium-priced single-injection products. With new single-injection therapies poised to enter the market in 2012 alongside growing awareness of these devices, the HA viscosupplementation market will represent an increasingly significant portion of the orthopedic biomaterial market. The knee cartilage repair market, which includes both grafts and devices, will experience its strongest revenue growth over the middle of the forecast period, following the introduction of a new autologous chondrocyte implantation (ACI) product and tissue bank in the graft segment. Procedure growth in the knee cartilage repair market, however, will continue to be challenged by an increase in the proportion of procedures performed at cost-conscious ambulatory surgical centers. While the cell concentration system market will recognize more modest revenue growth than other orthopedic biomaterial segments due to inconclusive clinical results regarding the products' use in orthopedic applications, the market will nevertheless be boosted by sustained growth in procedures utilizing bone marrow aspirate (BMA) and bone marrow aspirate concentrate (BMAC), partly as a result of the aforementioned controversies surrounding INFUSE. The machined bone IBD market, meanwhile, will continue to experience significant obstacles to growth over the forecast period as surgeons increasingly adopt nonbone IBDs.

METHODOLOGY

RESEARCH METHODOLOGY

This report uses a number of methodologies to gather and present data and analysis. At the outset, a large survey of secondary sources is conducted. These sources act as the basis for the primary research stage, which builds and enhances the quantitative and qualitative attributes of the early research.

Secondary sources include

  • Government sources:
    • Securities and Exchange Commission filings
    • Food and Drug Administration and patent filings
    • National Center for Health Statistics data
  • Orthopedic biomaterial companies:
    • Annual reports, product brochures, corporate profiles, etc.
  • Internal databases and reports:
    • Previous reports on similar/related sources
  • General Internet searches, medical literature, and newspaper/magazine searches:
    • Identifying various centers of specialization and articles that might provide leads for primary research

The secondary research stage builds the foundation for the primary research.

The primary research methodology has four steps:

Step 1: The first step involves an impartial scan of all the information gathered during the secondary research stage to determine its utility based on the specific requirements of this report. Each piece of information is either discarded or marked as high- or low-priority and then organized appropriately as determined by the structure and sectioning of the report.

Step 2: At this stage, early assumptions are formed as to the implications of the information for the various orthopedic biomaterial market segments. These assumptions are then used to determine hypotheses using both inductive and deductive approaches. On the quantitative front, these hypotheses result in full historical and projected market data sets (market sizes - unit sales, average selling prices [ASPs], and revenues - as well as market shares).

Step 3: At this stage, the research is in position for its most important primary phase - expert interviews. Throughout the secondary research phase, industry and medical experts are identified.

These experts are then contacted by telephone and asked to participate in interviews on recent trends and developments in the industry. Interviews are either conducted at the time of the initial call or scheduled at the convenience of the expert. Interview questions are tailored to the expertise of each particular interviewee, although in most cases, the most important questions are asked of all experts.

The questions are largely based on the assumptions and hypotheses developed in Step 2, which are then augmented, discarded, or adjusted based on the views and positions put forth. Attempts are made, whenever possible, to cross-check the views of various experts against each other and to reach positions of consensus on issues and market numbers.

In addition, orthopedic surgeons are surveyed and interviewed. Physicians are asked to comment on various issues/trends, both in their own practice and in the overall market. The responses provided are then used to strengthen or augment the assumptions and hypotheses developed during the primary research phase.

Step 4: The final stage of primary research involves individual and group analysis by Millennium Research Group. All research results are assessed and cross-checked thoroughly to determine their validity, relevance, and weight. From this process, qualitative conclusions are reached and data points finalized.

FORECAST METHODOLOGY

In addition to the research methodology outlined above, the following “bottom-up” methodology is used to develop forecast assumptions for the report.

A comprehensive breakdown of various orthopedic biomaterial procedures and unit sales is prepared using data from several sources, including professional associations, government statistics, and private research/media sources. Industry experts and practitioners are consulted to ensure accuracy and verify observed trends. As a cross-check, total industry revenues available through annual reports and other sources are compared against modeled industry revenues.

Using the best estimates of industry experts, practitioners, private research/media sources, and inhouse experts, year-by-year growth rates and ASPs are applied individually to each subcategory to derive forecasts. These estimates are cross-checked by industry experts (marketing managers, product managers, CEOs, etc.) and further refined.

Overall findings are compared against market and procedure forecasts published by other sources to ensure reasonable estimates.

Companies mentioned in this report

  • Acologix
  • Aesculap
  • Allez Spine
  • AlloSource
  • Alphatec Spine
  • Amedica
  • Anika Therapeutics
  • ApaTech (acquired by Baxter in 2010)
  • Arteriocyte Medical Systems
  • Arthrex
  • Bacterin International
  • Baxter
  • Berkeley Advanced Biomaterials
  • Biocomposites
  • Biocoral
  • Biomet
  • BioMimetic Therapeutics
  • BioSyntech
  • Bone Bank Allografts
  • Bone Biologics
  • Bone Solutions
  • BONESUPPORT
  • Carticept Medical
  • Cascade Medical Enterprises
  • Cerapedics
  • COBE Cardiovascular (a Sorin Group company)
  • Collagen Matrix
  • Community Tissue Services
  • ConMed Linvatec
  • Core Dynamics
  • curasan
  • Cytomedix
  • DCI Donor Services
  • DePuy
  • EmCyte Corporation
  • ETEX
  • Exactech
  • Ferring Pharmaceuticals
  • FH ORTHOPEDICS
  • Fidia Farmaceutici
  • Geistlich Group
  • Genzyme Biosurgery
  • Globus Medical
  • Graftys
  • Histogenics
  • Implants International
  • Integra LifeSciences
  • SIGNUS Medical
  • Smith & Nephew
  • SpineCraft
  • Interpace BioPharma
  • ISTO Technologies
  • Jemo Spine
  • Joint Restoration Foundation
  • Kasios
  • Kensey Nash
  • Lanx
  • LDR Spine
  • LifeLink Tissue Bank
  • LifeNet Health
  • Life Spine
  • MEDICREA
  • Medtronic Spinal & Biologics
  • Mesoblast
  • Musculoskeletal Transplant Foundation
  • NexGen Biologics
  • NovaBone Products
  • NuVasive
  • Olympus Terumo Biomaterials
  • Ortho Development
  • Orthofix
  • Orthovita (Stryker acquisition announced in June 2011)
  • Osteohealth
  • Osteotech (acquired by Medtronic in 2010)
  • Performance Grafts
  • Pioneer Surgical Technology
  • Piramal Healthcare
  • ProChon Biotech (acquired by Histogenics in May 2011)
  • Q-Med (acquired by Galderma in December 2010)
  • Regenerative Sciences
  • RegenLab
  • RepRegen
  • Sanofi
  • Scil Technology
  • Seikagaku
  • Stryker
  • Synthes (to be acquired by Johnson & Johnson)
  • Terumo Americas Holding
  • TETEC Tissue Engineering Technologies (a subsidiary of Aesculap)
  • ThermoGenesis
  • TiGenix
  • Tissue Banks International
  • Tornier
  • UCSD Tissue Bank
  • University of Miami Tissue Bank
  • VERTEBRON
  • Vidacare
  • Wright Medical Technology
  • Zimmer

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

1.0. CLINICAL LANDSCAPE

  • 1.1. Background
    • 1.1.1. Osteoarthritis
    • 1.1.2. Knee Cartilage Injuries
  • 1.2. Procedure Overview
    • 1.2.1. Bone Graft Procedures
      • 1.2.1.1. Trauma Surgeries
      • 1.2.1.2. Large-Joint Revision and Reconstruction Procedures
      • 1.2.1.3. Thoracolumbar and Cervical Spinal Fusions
      • 1.2.1.4. Craniomaxillofacial Surgeries
      • 1.2.1.5. Extremity Surgeries
    • 1.2.2. Hyaluronic Acid Viscosupplementation Treatments
    • 1.2.3. Interbody Fusions
    • 1.2.4. Cell Concentration System Procedures
    • 1.2.5. Knee Cartilage Repairs
      • 1.2.5.1. Debridement and Microfracture
      • 1.2.5.2. Osteochondral Flap Repairs
      • 1.2.5.3. Osteochondral Autograft Transplantation
      • 1.2.5.4. Osteochondral Allograft Transplantation
      • 1.2.5.5. Autologous Chondrocyte Implantation
      • 1.2.5.6. Cell-Free Technologies
    • 1.2.6. Competing Treatments
    • 1.2.7. Emerging Competing Treatments and Technologies
  • 1.3. Country Overview
    • 1.3.1. Demographics and Economy
    • 1.3.2. Health Care System
    • 1.3.3. Regulatory Environment

2.0. PRODUCTS

  • 2.1. Overview
    • 2.1.1. Products Covered
  • 2.2. Bone Grafts
    • 2.2.1. Functions
      • 2.2.1.1. Autografts
      • 2.2.1.2. Growth Factors
      • 2.2.1.3. Demineralized Bone Matrices
      • 2.2.1.4. First-Generation Synthetics
      • 2.2.1.5. Second-Generation Synthetics
      • 2.2.1.6. Orthopedic Stem Cell Products
      • 2.2.1.7. Nonproprietary Allografts
    • 2.2.2. Differentiating Features
    • 2.2.3. Emerging Products
  • 2.3. Hyaluronic Acid Viscosupplementation Products
    • 2.3.1. Functions
    • 2.3.2. Differentiating Features
    • 2.3.3. Emerging Products
  • 2.4. Machined Bone Interbody Devices
    • 2.4.1. Functions
  • 2.5. Cell Concentration Systems
    • 2.5.1. Functions
      • 2.5.1.1. Platelet Concentration Systems
      • 2.5.1.2. Bone Marrow Aspirate Concentrate Systems
      • 2.5.1.3. Bone Marrow Aspirate Systems
      • 2.5.1.4. Emerging Products
  • 2.6. Knee Cartilage Repair Products
    • 2.6.1. Functions
    • 2.6.2. Emerging Products
      • 2.6.2.1. Next-Generation Autologous Chondrocyte Implantation Products
        • DePuy Mitek's Cartilage Autograft Implantation System
        • Fidia Advanced Biopolymers' Hyalograft C and TiGenix's ChondroCelect
        • Genzyme Biosurgery's Matrix-Induced Autologous Chondrocyte Implantation
        • Histogenics' VeriCart and NeoCart
        • ProChon Biotech's BioCart
        • TETEC Tissue Engineering Technologies' NOVOCART 3D
      • 2.6.2.2. Biomaterials
        • BioMimetic Therapeutics' Augment C and Augment LT
        • BioSyntech's BST-CarGel
        • Core Dynamics' Preserved Osteochondral Dowels
        • Kensey Nash's Cartilage Repair Device
        • Scil Technology's ST03
        • Zimmer and ISTO Technologies' DeNovo ET Engineered Tissue Graft
      • 2.6.2.3. Synthetics
        • Carticept Medical's Cartiva Synthetic Cartilage Implant
        • SaluMedica's SaluCartilage

3.0. CLINICAL TRIALS

  • 3.1. Completed Clinical Trials
  • 3.2. Ongoing Clinical Trials

4.0. BRANDS AND COMPETITIVE ANALYSIS

  • 4.1. Overview
    • 4.1.1. Competitive Snapshot
    • 4.1.2. Market Shares
    • 4.1.3. Recent Events
  • 4.2. Bone Graft Substitute Market
    • 4.2.1. Competitive Snapshot
    • 4.2.2. Detailed Competitive Landscape
    • 4.2.3. Current Market Shares
    • 4.2.4. Recent Events
  • 4.3. Hyaluronic Acid Viscosupplementation Market
    • 4.3.1. Competitive Snapshot
    • 4.3.2. Detailed Competitive Landscape
    • 4.3.3. Current Market Shares
    • 4.3.4. Recent Events
  • 4.4. Machined Bone Interbody Device Market
    • 4.4.1. Competitive Snapshot
    • 4.4.2. Detailed Competitive Landscape
    • 4.4.3. Current Market Shares
    • 4.4.4. Recent Events
  • 4.5. Cell Concentration System Market
    • 4.5.1. Competitive Snapshot
    • 4.5.2. Detailed Competitive Landscape
    • 4.5.3. Current Market Shares
    • 4.5.4. Recent Events
  • 4.6. Knee Cartilage Repair Market
    • 4.6.1. Competitive Snapshot
    • 4.6.2. Detailed Competitive Landscape
    • 4.6.3. Current Market Shares
    • 4.6.4. Recent Events

5.0. ORTHOPEDIC BIOMATERIAL MARKET OUTLOOK

  • 5.1. Market Snapshot
  • 5.2. Market Overview

6.0. BONE GRAFT SUBSTITUTE MARKET OUTLOOK

  • 6.1. Market Snapshot
  • 6.2. Detailed Market Overview
    • 6.2.1. Market Overview by Material
      • 6.2.1.1. Autografts (Procedures Only)
      • 6.2.1.2. Growth Factor Market
      • 6.2.1.3. Demineralized Bone Matrix Market
      • 6.2.1.4. First-Generation Synthetics Market
      • 6.2.1.5. Second-Generation Synthetics Market
      • 6.2.1.6. Orthopedic Stem Cell Product Market
      • 6.2.1.7. Nonproprietary Allograft Market
    • 6.2.2. Market Overview by Procedure Type
      • 6.2.2.1. Spinal Fusion Bone Graft Substitute Market
        • Spinal Fusion Bone Graft Substitute Market by Procedure Type
        • Posterolateral and Interbody Fusion Bone Graft Substitute Market
        • Spinal Fusion Bone Graft Substitute Market by Anatomy
        • Thoracolumbar Fusion Bone Graft Substitute Market
        • Cervical Fusion Bone Graft Substitute Market
      • 6.2.2.2. Trauma Surgery Bone Graft Substitute Market
      • 6.2.2.3. Large-Joint Revision and Reconstruction Bone Graft Substitute Market
      • 6.2.2.4. Craniomaxillofacial Surgery Bone Graft Substitute Market
      • 6.2.2.5. Extremity Surgery Bone Graft Substitute Market

7.0. HYALURONIC ACID VISCOSUPPLEMENTATION MARKET OUTLOOK

  • 7.1. Market Snapshot
  • 7.2. Detailed Market Overview
    • 7.2.1. Market Overview by Number of Injections
    • 7.2.2. Market Overview by Anatomy (Procedures Only)
    • 7.2.3. Market Overview by Facility Type (Qualitative Discussion Only)

8.0. MACHINED BONE INTERBODY DEVICE MARKET OUTLOOK

  • 8.1. Market Snapshot
  • 8.2. Detailed Market Overview

9.0. CELL CONCENTRATION SYSTEM MARKET OUTLOOK

  • 9.1. Market Snapshot
  • 9.2. Detailed Market Overview

10.0. KNEE CARTILAGE REPAIR MARKET OUTLOOK

  • 10.1. Overview
    • 10.1.1. Market Snapshot
    • 10.1.2. Detailed Market Overview
      • 10.1.2.1. Debridement and Microfracture (Procedures Only)
  • 10.2. Knee Cartilage Repair Graft Market
    • 10.2.1. Market Snapshot
    • 10.2.2. Detailed Market Overview
      • 10.2.2.1. Osteochondral Allograft Market
      • 10.2.2.2. Autologous Chondrocyte Implantation Market
  • 10.3. Knee Cartilage Repair Device Market
    • 10.3.1. Market Snapshot
    • 10.3.2. Detailed Market Overview
      • 10.3.2.1. Osteochondral Flap Repair Device Market
      • 10.3.2.2. Osteochondral Autograft Instrument Kit Market

APPENDIX A: METHODOLOGY

APPENDIX B: MRG ACRONYMS AND INITIALISMS

APPENDIX C: BIBLIOGRAPHY

LIST OF FIGURES AND TABLES

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

  • Figure 1: Orthopedic Biomaterial Market, by Product Type, US (US$), 2010 - 2016
  • Table 1: Orthopedic Biomaterial Market Landscape, US (US$), 2011 and 2016
  • Table 2: Orthopedic Biomaterial Market Leaders, by Product Type and Revenue, US, 2011
  • Table 3: Most Promising Emerging Technologies in the Orthopedic Biomaterial Market, US, 2011 - 2016
  • Table 4: Expected Key Events in the Orthopedic Biomaterial Market, US, 2012 - 2016
  • Table 5: Factors Impacting the Orthopedic Biomaterial Market, by Product Type, US, 2011 - 2016
  • Table 6: Companies Mentioned in This Report
  • Table 7: Key Report Updates, 2012

1.0 CLINICAL LANDSCAPE

  • Table 8: Emerging Competing Treatments in Development, US, 2011 - 2016
  • Table 9: Key Health and Economic Indicators, US, 2011

2.0 PRODUCTS

  • Table 10: Orthopedic Biomaterial Market, by Product Type, US
  • Table 11: Characteristics of Bone Grafts, by Material
  • Table 12: Select First-Generation Synthetic BGS Materials, by Material
  • Table 13: Advantages and Disadvantages of Bone Grafts, by Material
  • Table 14: Emerging Products for the BGS Market, US, 2011 - 2016
  • Table 15: Advantages and Disadvantages of HA Viscosupplementation Products, by Number of Injections
  • Table 16: Emerging Products in Development for the Cell Concentration System Market, US, 2011 - 2016
  • Table 17: Knee Cartilage Repair Products, by Product Type

3.0 CLINICAL TRIALS

  • Table 18: Summary of Promoting Fusion in Minimally Invasive Lumbar Interbody Stabilization with Low-Dose BMP-2 - But What is the Cost?
  • Table 19: Summary of STAR
  • Table 20: Summary of SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder Study
  • Table 21: Summary of Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)
  • Table 22: Summary of A Double-blind RCT of a Single Dose of Hyaluronan in the Treatment of Osteoarthritis of the Ankle
  • Table 23: Summary of Growth Factor and Catabolic Cytokine Concentrations are Influenced by the Cellular Composition of PRP Study
  • Table 24: Summary of ORTHOVISC Shoulder RCT (OV Shoulder)
  • Table 25: Efficacy and Safety of Accell Evo3 DBM in Instrumented Posterolateral Lumbar Spine Fusion
  • Table 26: Summary of an Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation
  • Table 27: Summary of APPRAISET1
  • Table 28: Summary of INFUSE Bone Graft/PEEK Interbody Spacer/Anterior Cervical Plate Pivotal Clinical Trial (ACDF)
  • Table 29: Summary of Comparing Synthetic Bone Alone Versus Synthetic Bone With Bone Marrow in Bone Lesions
  • Table 30: Summary of Platelet Rich Plasma (PRP) in Total Knee Replacement Study
  • Table 31: Summary of CAIS for the Repair of Knee Cartilage Through Cartilage Regeneration

4.0 BRANDS AND COMPETITIVE ANALYSIS

  • Table 32: Leading Competitors in the Orthopedic Biomaterial Market, by Product Type, as a % of Total, US, 2011
  • Table 33: Recent Events in the Orthopedic Biomaterial Market, US, 2011
  • Table 34: Leading Competitors in the BGS Market, by Material, as a % of Total, US, 2011
  • Table 35: Recent Events in the BGS Market, US, 2011
  • Table 36: Leading Competitors in the HA Viscosupplementation Market, as a % of Total, US, 2011
  • Table 37: Recent Events in the HA Viscosupplementation Market, US, 2011
  • Table 38: Leading Competitors in the Machined Bone IBD Market, as a % of Total, US, 2010
  • Table 39: Recent Events in the Machined Bone IBD Market, US, 2011
  • Table 40: Leading Competitors in the Cell Concentration System Market, by Procedure Type, as a % of Total, US, 2011
  • Table 41: Recent Events in the Cell Concentration Systems Market, US, 2011
  • Table 42: Leading Competitors in the Knee Cartilage Repair Market, by Product Type, as a % of Total, US, 2010
  • Table 43: Leading Competitors in the Knee Cartilage Repair Graft Market, by Product Type, US, 2010
  • Table 44: Leading Competitors in the Knee Cartilage Repair Device Market, by Type, US, 2010
  • Table 45: Recent Events in the Knee Cartilage Repair Market, US, 2011

5.0 ORTHOPEDIC BIOMATERIAL MARKET OUTLOOK

  • Figure 2: Orthopedic Biomaterial Market Growth, by Product Type, US (US$), 2011 - 2016
  • Table 46: Factors Impacting the Orthopedic Biomaterial Market, by Product Type, US, 2011 - 2016
  • Table 47: Orthopedic Biomaterial Market, by Product Type, US (US$), 2010 - 2016

6.0 BONE GRAFT SUBSTITUTE MARKET OUTLOOK

  • Figure 3: BGS Market, by Material, US (US$), 2010 - 2016
  • Table 48: Factors Impacting the Cell Concentration System Market, US, 2011 - 2016
  • Table 49: Bone Graft Procedures, by Procedure Type, US, 2010 - 2016
  • Table 50: Average Volume of Bone Graft per Procedure, by Procedure Type, US, 2011
  • Table 51: Bone Graft Units, by Material, US, 2010 - 2016
  • Table 52: BGS Market, by Procedure Type, US (US$), 2010 - 2016
  • Table 53: BGS ASPs, by Material and Volume, US (US$), 2011
  • Table 54: BGS Market, by Material, US (US$), 2010 - 2016
  • Table 55: Spinal Fusion Bone Graft Procedures, by Procedure Type, US, 2010 - 2016
  • Table 56: Spinal Fusion Bone Graft Units, by Material, US, 2010 - 2016
  • Table 57: Spinal Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 58: Spinal Fusion Bone Graft Procedures, by Procedure Type, US, 2010 - 2016
  • Table 59: Spinal Fusion BGS ASPs, by Procedure Type, US (US$), 2010-2016
  • Table 60: Spinal Fusion BGS Market, by Procedure Type, US (US$), 2010 - 2016
  • Table 61: Posterolateral Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 62: Interbody Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 63: Thoracolumbar Fusion Bone Graft Procedures, by Number of Levels, US, 2010 - 2016
  • Table 64: Thoracolumbar Fusion Bone Graft Units, by Material, US, 2010 - 2016
  • Table 65: Single-Level Thoracolumbar Fusion Bone Graft Units, by Material, US, 2010 - 2016
  • Table 66: Two-Level Thoracolumbar Fusion Bone Graft Units, by Material, US, 2010 - 2016
  • Table 67: Multilevel Thoracolumbar Fusion Bone Graft Units, by Material, US, 2010 - 2016
  • Table 68: Thoracolumbar Fusion BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 69: Single-Level Thoracolumbar Fusion BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 70: Two-Level Thoracolumbar Fusion BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 71: Multilevel Thoracolumbar Fusion BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 72: Thoracolumbar Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 73: Single-Level Thoracolumbar Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 74: Two-Level Thoracolumbar Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 75: Multilevel Thoracolumbar Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 76: Cervical Fusion Bone Graft Procedures, by Number of Levels, US, 2010 - 2016
  • Table 77: Cervical Fusion Bone Graft Units, by Material, US, 2010 - 2016
  • Table 78: Single-Level Cervical Fusion Bone Graft Units, by Material, US, 2010 - 2016
  • Table 79: Two-Level Cervical Fusion Bone Graft Units, by Material, US, 2010 - 2016
  • Table 80: Multilevel Cervical Fusion Bone Graft Units, by Material, US, 2010 - 2016
  • Table 81: Cervical Fusion BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 82: Single-Level Cervical Fusion BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 83: Two-Level Cervical Fusion BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 84: Multilevel Cervical Fusion BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 85: Cervical Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 86: Single-Level Cervical Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 87: Two-Level Cervical Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 88: Multilevel Cervical Fusion BGS Market, by Material, US (US$), 2010 - 2016
  • Table 89: Trauma Surgery Bone Graft Procedures, by Application, US, 2010 - 2016
  • Table 90: Trauma Surgery Bone Graft Units, by Material, US, 2010 - 2016
  • Table 91: Trauma Surgery BGS Market, by Material, US (US$), 2010 - 2016
  • Table 92: Fresh Fracture Surgeries, by Technique, US, 2010 - 2016
  • Table 93: Fresh Fracture Surgery Bone Graft Units, by Material, US, 2010 - 2016
  • Table 94: Fresh Fracture Surgery BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 95: Fresh Fracture Surgery BGS Market, by Material, US (US$), 2010 - 2016
  • Table 96: Nonunion Surgery Bone Graft Units, by Material, US, 2010 - 2016
  • Table 97: Nonunion Surgery BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 98: Nonunion Surgery BGS Market, by Material, US (US$), 2010 - 2016
  • Table 99: Large-Joint Revision and Reconstruction Bone Graft Procedures, by Application, US, 2010 - 2016
  • Table 100: Large-Joint Revision and Reconstruction Bone Graft Units, by Material, US, 2010 - 2016
  • Table 101: Large-Joint Revision and Reconstruction BGS Market, by Material, US (US$), 2010 - 2016
  • Table 102: Hip Revisions, by Technique, US, 2010 - 2016
  • Table 103: Hip Revision Bone Graft Units, by Material, US, 2010 - 2016
  • Table 104: Hip Revision BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 105: Hip Revision BGS Market, by Material, US (US$), 2010 - 2016
  • Table 106: Knee Revisions, by Technique, US, 2010 - 2016
  • Table 107: Knee Revision Bone Graft Units, by Material, US, 2010 - 2016
  • Table 108: Knee Revision BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 109: Knee Revision BGS Market, by Material, US (US$), 2010 - 2016
  • Table 110: Primary Total Knee Replacements, by Technique, US, 2010 - 2016
  • Table 111: Primary Total Knee Replacement Bone Graft Units, by Material, US, 2010 - 2016
  • Table 112: Primary Total Knee Replacement BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 113: Primary Total Knee Replacement BGS Market, by Material, US (US$), 2010 - 2016
  • Table 114: Primary Total Hip Replacements, by Technique, US, 2010 - 2016
  • Table 115: Primary Total Hip Replacement Bone Graft Units, by Material, US, 2010 - 2016
  • Table 116: Primary Total Hip Replacement BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 117: Primary Total Hip Replacement BGS Market, by Material, US (US$), 2010 - 2016
  • Table 118: CMF Surgery Procedures, by Technique, US, 2010 - 2016
  • Table 119: CMF Surgery Bone Graft Units, by Material, US, 2010 - 2016
  • Table 120: CMF Surgery BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 121: CMF Surgery BGS Market, by Material, US (US$), 2010 - 2016
  • Table 122: Extremity Surgeries, by Technique, US, 2010 - 2016
  • Table 123: Extremity Surgery Bone Graft Units, by Material, US, 2010 - 2016
  • Table 124: Extremity Surgery BGS ASPs, by Material, US (US$), 2010 - 2016
  • Table 125: Extremity Surgery BGS Market, by Material, US (US$), 2010 - 2016

7.0 HYALURONIC ACID VISCOSUPPLEMENTATION MARKET OUTLOOK

  • Figure 4: HA Viscosupplementation Market, US (US$), 2010 - 2016
  • Table 126: Factors Impacting the HA Viscosupplementation Market, US, 2011 - 2016
  • Table 127: HA Viscosupplementation Treatments and Injections, US, 2010 - 2016
  • Table 128: HA Viscosupplementation Treatments, by Number of Injections, US, 2010 - 2016
  • Table 129: HA Viscosupplementation Treatments, by Anatomy, US, 2010 - 2016
  • Table 130: HA Viscosupplementation Treatment Growth, by Anatomy, US, 2011 - 2016
  • Table 131: HA Viscosupplementation Treatments, by Anatomy, as a % of Total, US, 2010 - 2016
  • Table 132: HA Viscosupplementation Market, US (US$), 2010 - 2016

8.0 MACHINED BONE INTERBODY DEVICE MARKET OUTLOOK

  • Figure 5: Machined Bone IBD Market, by Approach, US (US$), 2010-2016
  • Table 133: Factors Impacting the Machined Bone IBD Market, US, 2011 - 2016
  • Table 134: Machined Bone IBD Procedures, by Approach, US, 2010 - 2016
  • Table 135: Machined Bone IBD Market, by Approach, US (US$), 2010 - 2016
  • Table 136: Machined Bone IBD Market Growth, by Approach, US, 2011 - 2016
  • Table 137: Machined Bone IBD Market, by Approach, as a % of Total, US, 2010 - 2016
  • Table 138: Machined Bone IBD Market, by Anatomy, US (US$), 2010 - 2016
  • Table 139: Machined Bone IBD Market Growth, by Anatomy, US, 2011 - 2016
  • Table 140: Machined Bone IBD Market, by Anatomy, as a % of Total, US, 2010 - 2016

9.0 CELL CONCENTRATION SYSTEM MARKET OUTLOOK

  • Figure 6: Cell Concentration System Market, by Product Type, US (US$), 2010 - 2016
  • Table 141: Factors Impacting the Cell Concentration System Market, US, 2011 - 2016
  • Table 142: Cell Concentration System Procedures, by Product Type, US, 2010 - 2016
  • Table 143: Cell Concentration System Procedures, by Procedure Type, US, 2010 - 2016
  • Table 144: Platelet Concentration Procedures, by Procedure Type, US, 2010 - 2016
  • Table 145: BMAC Procedures, by Procedure Type, US, 2010 - 2016
  • Table 146: BMA Procedures, by Procedure Type, US, 2010 - 2016
  • Table 147: Cell Concentration System Market, by Product Type, US (US$), 2010 - 2016
  • Table 148: Cell Concentration System Market Growth, by Product Type, US, 2011 - 2016
  • Table 149: Cell Concentration System Market, by Product Type, as a % of Total, US, 2010 - 2016

10.0 KNEE CARTILAGE REPAIR MARKET OUTLOOK

  • Figure 7: Knee Cartilage Repair Market, by Product Type, US (US$), 2010 - 2016
  • Table 150: Factors Impacting the Knee Cartilage Repair Market, by Product Type, US, 2011 - 2016
  • Table 151: Knee Cartilage Repairs, by Procedure Type, US, 2010 - 2016
  • Table 152: Knee Cartilage Repair Market, by Product Type, US (US$), 2010 - 2016
  • Table 153: Knee Cartilage Repair Graft Market, by Procedure Type, US (US$), 2010 - 2016
  • Table 154: Knee Cartilage Repair Graft Market Growth, by Procedure Type, US, 2011 - 2016
  • Table 155: Knee Cartilage Repair Graft Market, by Procedure Type, as a % of Total, US, 2010 - 2016
  • Table 156: Knee Cartilage Repair Device Market, by Procedure Type, US (US$), 2010 - 2016
  • Table 157: Knee Cartilage Repair Device Market Growth, by Procedure Type, US, 2011 - 2016
  • Table 158: Knee Cartilage Repair Device Market, by Procedure Type, as a % of Total, US, 2010 - 2016

APPENDIX A: METHODOLOGY

APPENDIX B: MRG ACRONYMS AND INITIALISMS

  • MRG Acronyms and Initialisms

APPENDIX C: BIBLIOGRAPHY

Back to Top